ProKidney Corp.
rilparencel
chronic kidney disease (CKD)
Resolved
187days ago
Phase 2 readout · Jan 1, 2026
What's at stake
Phase 2 trial results for rilparencel in chronic kidney disease (CKD) are due Jan 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 17h ago
“Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the American Society of Nephrology (CJASN) in January 2026.”